Here's Why Everyone's Talking About Summit Therapeutics

Motley Fool09-17

A bispecific antibody Summit Therapeutics licensed from Akeso outperformed the world's best-selling cancer therapy. In a phase 3 trial, treatment with ivonescimab reduced patients' risk of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468533587?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F790857%2Finvestment-presentation-getty.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-09-17 16:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468533587","market":"us","top_or_hot":-1,"title":"Here's Why Everyone's Talking About Summit Therapeutics","media":"Motley Fool","content":"<div>\n<p>A bispecific antibody Summit Therapeutics licensed from Akeso outperformed the world's best-selling cancer therapy.\n\n\n\n\n\n\n\nIn a phase 3 trial, treatment with ivonescimab reduced patients' risk of ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/09/17/heres-why-everyones-talking-about-summit-therapeut/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Everyone's Talking About Summit Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Everyone's Talking About Summit Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-17 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/09/17/heres-why-everyones-talking-about-summit-therapeut/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A bispecific antibody Summit Therapeutics licensed from Akeso outperformed the world's best-selling cancer therapy.\n\n\n\n\n\n\n\nIn a phase 3 trial, treatment with ivonescimab reduced patients' risk of ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/09/17/heres-why-everyones-talking-about-summit-therapeut/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765489.SGD","symbol_name":"FTIF - Franklin Mutual US Value A Acc SGD","start_time":0,"source_url":"https://www.fool.com/investing/2024/09/17/heres-why-everyones-talking-about-summit-therapeut/","article_id":"2468533587","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F790857%2Finvestment-presentation-getty.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468533587","pubTimestamp":1726561440,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0861579265.USD":"联博低波幅策略股票基金A","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","SMMF":"Summit Financial Group","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","BK4516":"特朗普概念","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","BK4139":"生物科技","MRK":"默沙东","BK4007":"制药","BK4211":"区域性银行","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","SMMT":"Summit Therapeutics PLC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4559":"巴菲特持仓","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LENZ":"Therapeutics","TIL":"Instil Bio, Inc.","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4550":"红杉资本持仓","BK4588":"碎股","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4505":"高瓴资本持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BNTX":"BioNTech SE"},"translate_title":"这就是为什么每个人都在谈论Summit Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1,"SMMF":1,"LENZ":1,"MRK":0.9,"TIL":0.7,"BNTX":0.7},"content_text":"A bispecific antibody Summit Therapeutics licensed from Akeso outperformed the world's best-selling cancer therapy.\n\n\n\n\n\n\n\nIn a phase 3 trial, treatment with ivonescimab reduced patients' risk of disease progression by 49% compared to Keytruda. \n\n\n\n\n\n\n\nInstil Bio and BioNTech are also developing in-licensed bispecific antibodies similar to ivonescimab.\n\nSeptember has been an exciting time for investors with their fingers on the pulse of cancer drug development. In a nutshell, it looks like the world's top-selling cancer therapy could have a serious competitor.Sales of Keytruda from Merck reached $25 billion last year thanks to its position as a standard first line of treatment for most patients newly diagnosed with the most common form of lung cancer.Biotech investors have been buzzing with enthusiasm for Summit Therapeutics (SMMT -7.67%) and its lead candidate, ivonescimab. Recently announced results from a clinical trial with frontline lung cancer patients showed ivonescimab reduced their risk of disease worsening by 49% compared to Keytruda monotherapy. That's a big deal for Summit and a pair of companies that are also developing candidates similar to ivonescimab, Instil Bio (TIL -23.91%) and BioNTech (BNTX 0.06%).Why Instil Bio and BioNTech are along for the rideKeytruda is an antibody that binds to programmed death receptors (PD-1) on the surface of immune cells. This checkpoint is supposed to keep those cells from destroying healthy tissue, but tumor cells often hijack the system. By displaying a programmed death ligand (PD-L1) on their surface, tumor cells often shut down immune systems before they can do their job.Keytruda is sometimes dosed in combination with a vascular endothelial growth factor (VEGF) inhibitor called Avastin. Instead of delivering two therapies, ivonescimab from Summit Therapeutics, IMM2510 from Instil Bio, and BNT327 from BioNTech are all bispecific antibodies that inhibit VEGF and the PD-1 checkpoint simultaneously.BispecificAntibodyChineseOwnerDevelopmentPartnerPD-1TargetVEGFTargetDevelopmentStageIvonescimabAkesoSummit TherapeuticsPD-1VEGF-AApproved in China. Phase 3 in U.S.IMM2510ImmuneOncoInstil BioPD-L1Multiple VEGF ligandsPhase 2BNT327BiotheusBioNTechPD-L1VEGF-APhase 3Table by author. Data sources: Summit Therapeutics, Instil Bio, and BioNTech.Shares of Instil Bio and BioNTech have risen sharply since Summit shared phase 3 results that show a strong progression-free survival benefit versus Keytruda. While their candidates are similar to Summit's, there are significant differences that could make them more or less effective.In terms of market value, Instil Bio was circling the drain when Summit began announcing success with its bispecific PD-1/VEGF drug. Since Instil started from such a low point, the clinical-stage biotech's stock price was able to shoot more than 500% higher in response to Summit's news.Time to buy?Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion annually, it's not hard to imagine blockbuster sales for a therapy that outperformed it in the important lung cancer setting.There are a lot of expectations for ivonescimab already baked into Summit Health's stock price. At last glance, it boasted a $22.7 billion market cap that could come crashing down if subsequent data for ivonescimab is anything less than spectacular.SMMT Market Cap data by YCharts.While ivonescimab outperformed Keytruda monotherapy, Merck's drug is usually combined with chemotherapy to treat lung cancer. We still don't know how well ivonescimab stands up to Keytruda and other PD-1 drugs when they're combined with chemotherapy.Another important uncertainty regarding Summit is ivonescimab's performance versus Keytruda plus Avastin. In theory, a bispecific antibody should be more effective than two traditional antibodies dosed simultaneously, but we can't be certain without another clinical trial.If investors want to bet on a bispecific PD-1/VEGF antibody, Instil Bio could be the better option. IMM2510 is in a much earlier stage of development, but Instil's market cap of about $456 million at recent prices is tiny for a company that could have a blockbuster lung cancer drug in its pipeline.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468533587"}